Document Detail

Experiences with continuous intraarterial administration of recombinant interferon alpha-2C (rIFN-alpha 2) for treatment of patients with advanced transitional cell bladder cancer.
MedLine Citation:
PMID:  3188978     Owner:  NLM     Status:  MEDLINE    
The response of locally-advanced transitional cell carcinoma of the urinary bladder to intraarterial regional treatment with recombinant interferon alpha-2C (rIFN-alpha 2) was investigated. Patients received 4-weekly courses of i.a. continuous infusion of rIFN-alpha 2 (5 megaunits/24 hours administered into the a. iliaca interna via a subcutaneously implanted port-a-cath) alternating with 4 weeks i.m. treatment cycles (5 megaunits/day x 3 weekly). None of the 5 patients entered in the study showed evidence of objective tumor regression after a median of 4 i.a./i.m. treatment cycles. Constitutional, organ and local toxic effects were considerable even with that low-dosage schedule employed. The lack of efficacy and poor tolerance of the regimen suggest that i.a. administration of IFN is unlikely to yield an acceptable therapeutic index.
W Scheithauer; G Theyer; O Zechner; H Ludwig
Related Documents :
2205028 - Alpha-2 interferon and 5-fluorouracil in advanced colorectal cancer.
9007858 - The treatment of recurrent unresectable and malignant meningiomas with interferon alpha...
15955138 - Treatment of idiopathic pulmonary fibrosis: is there anything new?
21540668 - Safety profile of trabectedin in combination with liposomal pegylated doxorrubicin in r...
18576918 - Toxicology study of repeat intracerebral administration of a measles virus derivative p...
16169678 - Clinical investigation: regional nodal failure patterns in breast cancer patients treat...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of biological regulators and homeostatic agents     Volume:  2     ISSN:  0393-974X     ISO Abbreviation:  J. Biol. Regul. Homeost. Agents     Publication Date:    1988 Apr-Jun
Date Detail:
Created Date:  1988-12-02     Completed Date:  1988-12-02     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8809253     Medline TA:  J Biol Regul Homeost Agents     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  67-70     Citation Subset:  IM    
Department of Internal Medicine II, Vienna University School of Medicine, Austria.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Carcinoma, Transitional Cell / therapy*
Infusions, Intra-Arterial
Interferon Type I, Recombinant / adverse effects,  pharmacokinetics,  therapeutic use*
Middle Aged
Urinary Bladder Neoplasms / therapy*
Reg. No./Substance:
0/Interferon Type I, Recombinant

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Activation of natural killer cell function during interferon-alpha treatment of patients with condyl...
Next Document:  Cardiac ruptures in northern Norway. A retrospective study of 104 cases.